+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Automated Cell Processing System Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Cell Therapy Processing Step, Scale of Operation, End User and Key Geographical Regions- Product Image
Automated Cell Processing System Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Cell Therapy Processing Step, Scale of Operation, End User and Key Geographical Regions- Product Image
New

Automated Cell Processing System Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Cell Therapy Processing Step, Scale of Operation, End User and Key Geographical Regions

  • PDF Icon

    Report

  • 184 Pages
  • March 2026
  • Region: Global
  • Roots Analysis
  • ID: 6171034
Description Jump to:
The global automated cell processing system market valued at USD 220 million in the current year is projected to grow at a CAGR of 16% during the forecast period.

The market sizing and opportunity analysis has been segmented across the following parameters:

Cell Therapy Processing Step

  • Apheresis
  • Separation
  • Expansion
  • Harvest
  • Fill / Finish
  • Cryopreservation
  • Thawing

Scale of Operation

  • Pre-clinical / Clinical Operations
  • Commercial Organizations

End User

  • Hospitals / Medical Centers / Clinics / Research Institutes / Academic Institutes
  • Cell Therapy Manufacturers / Developers

Key Geographical Regions

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and North Africa

AUTOMATED CELL PROCESSING SYSTEM MARKET: GROWTH AND TRENDS

Various developmental breakthroughs in the biotechnology industry have resulted in an increase in the number of cell therapy candidates. In fact, more than 2,000 cell and gene therapy candidates are currently being investigated for the treatment of a myriad of disease indications. Further, the findings from FDA-approved therapies showcased the significant potential of cellular therapies in the treatment of oncological disorders, rare diseases, and chronic diseases. As a result, this treatment approach has garnered considerable attention from players engaged in the healthcare industry in recent years. Nevertheless, the conventional cell therapy manufacturing process is labor-intensive and time-consuming leading to heightened production costs. In addition, this manual process of cell therapy manufacturing leads to batch-to-batch variations. Thus, there is an urgent and growing demand for more advanced and time-efficient solutions.


Over the years, several advanced and innovative automation tools and technologies have been developed. These automated and closed cell processing systems have been demonstrated to hold the potential for significant reduction in the cost associated with the manufacturing of advanced cell therapies. One such automated system, namely GMP-In-A Box, offers several advantages, including increased throughput, decreased idle time between batch runs and reduced manual labor. Owing to such benefits of automation, the cell processing systems market is poised to witness lucrative growth in the coming future.

AUTOMATED CELL PROCESSING SYSTEM MARKET: KEY INSIGHTS

The report delves into the current state of the automated cell processing system market and identifies potential growth opportunities within industry. Some key findings from the report include:

  • Presently, over 60 innovative, automated and closed systems have been developed by different companies in order to automate various stages of cell therapy development, production, and cryopreservation.
  • The market landscape is fragmented, featuring both established players and new entrants, engaged in developing novel technologies with distinct features, for processing cells across different scales of operation.
  • Since 2010, many startups, focused on developing automated and closed cell processing systems, have been established; this upcoming domain has captured the interest of both big and small players.
  • Majority of the available systems are compliant with the current regulatory requirements; examples include BATON, NANT 001, robotic cell culture systems and the volta loop.
  • The increasing interest of stakeholders in this field is also reflected in the recent partnership activity; most recent deals are focused on novel technologies and involve the active participation of both international and indigenous players.

  • The number of partnerships in this domain have increased at a CAGR of 24%; more than 70% of these partnerships have been signed since 2018.
  • Several deals focused on utilization or integration of SA25 aseptic filling work cell (vanrx pharma systems) were signed for fill / finish of cell therapy products.
  • In pursuit of a competitive advantage, equipment developers are presently focusing on the integration of advanced features into their respective products and affiliated offerings.
  • An evaluation of more than 300+ stakeholders engaged in the development of cell therapies, including big pharma players, reveals several likely strategic partnership opportunities for equipment providers in this field.
  • Given their cost saving potential across different processing steps, we expect the automated and closed cell therapy systems market to grow at an annualized rate of 16% over the next decade.


Example Players in the Automated Cell Processing System Market

  • AstraZeneca
  • Baxter
  • Bayer
  • Cytiva (Acquired by Danaher Corporation)
  • Cellular Therapeutics
  • Lonza
  • Merck
  • Pall (Acquired by Danaher Corporation)
  • Terumo BCT
  • ThermoGenesis

AUTOMATED CELL PROCESSING SYSTEM MARKET: RESEARCH COVERAGE

  • Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the global automated cell processing system market, focusing on key market segments, including [A] cell therapy processing step, [B] scale of operation, [C] end user and [D] key geographical regions.
  • Market Landscape: A comprehensive evaluation of the automated and closed systems, based on several relevant parameters, such as [A] cell therapy processing step, [B] their key features, [C] product specifications, [D] type of cells supported, [E] type of cell culture, [F] scale of operation, [G] application, [H] end users, [I] key support services offered and [J] regulatory certification / accreditations obtained.
  • Product Competitiveness Analysis: A comprehensive competitive analysis of automated and closed systems, examining factors, such as [A] supplier power and [B] portfolio-related parameters.
  • Company Profiles: In-depth profiles of key players that are engaged in offering automated and closed cell therapy processing systems, focusing on [A] overview of the company, [B] financial information (if available), [C] detailed description of the system(s) they offer and [D] recent developments and an informed future outlook.
  • Partnerships and Collaborations: An insightful analysis of the deals inked by stakeholders in the automated cell processing system market, based on several parameters, such as [A] year of partnership, [B] type of partnership, [C] type of therapy, [D] type of cell processing step, [E] key automated and closed cell processing systems, [F] partner’s focus area, [G] most active players (in terms of number of partnerships signed), and [H] geographical location of collaborators.
  • Big Pharma Initiatives: A comprehensive evaluation of recent initiatives undertaken by big pharma players engaged in the automated cell processing system market.

KEY QUESTIONS ANSWERED IN THIS REPORT

  • How many companies are currently engaged in this market?
  • Which are the leading companies in this market?
  • What factors are likely to influence the evolution of this market?
  • What is the current and future market size?
  • What is the CAGR of this market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

  • The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
  • Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
  • The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

  • Complimentary PPT Insights Packs
  • Complimentary Excel Data Packs Covering All Analytical Modules
  • Up to 15% Complimentary Content Customization
  • In-Depth Report Walkthrough with the Research Team
  • Complimentary Report Update if the Report is 6+ Months Old

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.2.1. Research Assumptions
1.2.2. Project Methodology
1.2.3. Forecast Methodology
1.2.4. Robust Quality Control
1.2.5. Key Considerations
1.2.5.1. Demographics
1.2.5.2. Economic Factors
1.2.5.3. Government Regulations
1.2.5.4. Supply Chain
1.2.5.6. COVID Impact / Related Factors
1.2.5.7. Market Access
1.2.5.8. Healthcare Policies
1.2.5.9. Industry Consolidation
1.3 Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Context and Background
3.2. Cell Therapies
3.3. Cell Therapy Manufacturing
3.4. Key Challenges Associated with Manufacturing Cell Therapies
3.5. Overview of Automated and Closed Cell Processing Systems
3.5.1. Need for Automated and Closed Cell Processing in Cell Therapy Manufacturing
3.5.2. Advantages and Affiliated Challenges
3.6. Key Growth Drivers and Roadblocks
3.7. Recent Developments and Upcoming Trends
4. COMPETITIVE LANDSCAPE
4.1. Chapter Overview
4.2. Automated and Closed Cell Therapy Processing Systems: Overall Market Landscape
4.2.1. Analysis by Cell Processing Step
4.2.2. Analysis by Types of Cells
4.2.3. Analysis by Type of Culture
4.2.4. Analysis by Scale of Operation
4.2.5. Analysis by Key Features
4.2.6. Analysis by Application Area
4.2.7. Analysis by Regulatory Certifications / Accreditations
4.2.8. Analysis by End User
4.3. Automated and Closed Cell Therapy Processing Systems: Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Type of Support Service(s) Offered
4.3.4. Analysis by Location of Headquarters
5. PRODUCT COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Assumptions / Key Parameters
5.3. Methodology
5.4. Product Competitiveness Analysis
5.4.1. Automated and Closed Cell Processing Systems for Apheresis
5.4.2. Automated and Closed Cell Processing Systems for Separation
5.4.3. Automated and Closed Cell Processing Systems for Expansion
5.4.4. Automated and Closed Cell Processing Systems for Harvest
5.4.5. Automated and Closed Cell Processing Systems for Fill Finish
5.4.6. Automated and Closed Cell Processing Systems for Cryopreservation
5.4.7. Automated and Closed Cell Processing Systems for Thawing
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Cytiva
6.2.1. Company Overview
6.2.2. Product Portfolio
6.2.3. Recent Developments and Future Outlook
6.3. Pall
6.3.1. Company Overview
6.3.2. Product Portfolio
6.3.3. Recent Developments and Future Outlook
6.4. Terumo BCT
6.4.1. Company Overview
6.4.2. Product Portfolio
6.4.3. Financial Information
6.4.4. Recent Developments and Future Outlook
6.5 ThermoGenesis
6.5.1. Company Overview
6.5.2. Product Portfolio
6.5.3. Financial Information
6.5.4. Recent Developments and Future Outlook
7. PARTNERSHIPS
7.1. Chapter Overview
7.2. Partnership Models
7.3. Automated and Closed Cell Therapy Processing Systems: Recent Partnerships
7.3.1. Analysis by Year of Partnership
7.3.2. Analysis by Type of Partnership
7.3.3. Analysis by Type of Therapy
7.3.4. Analysis by Cell Processing Step
7.3.5. Analysis by Type of Automated and Closed Cell Processing Systems
7.3.6. Analysis by Partner’s Focus Area
7.3.7. Most Active Players: Analysis by Number of Partnerships
7.3.8. Geographical Analysis
7.3.8.1. Country-Wise Distribution
7.3.8.2. Intercontinental and Intracontinental Agreements
8. BIG PHARMA INITIATIVES IN AUTOMATED AND CLOSED CELL THERAPY PROCESSING SYSTEMS DOMAIN
8.1. Chapter Overview
8.2. Initiatives Undertaken by Big Pharma Players
8.2.1. Initiatives Undertaken by AbbVie
8.2.2. Initiatives Undertaken by Bristol Myers Squibb
8.2.3. Initiatives Undertaken by Gilead Sciences
8.2.4. Initiatives Undertaken by GlaxoSmithKline
8.2.5. Initiatives Undertaken by Johnson & Johnson
8.2.6. Initiatives Undertaken by Novartis
8.2.7. Initiatives Undertaken by Roche
8.2.8. Initiatives Undertaken by Sanofi
8.2.9. Initiatives Undertaken by Takeda Pharmaceutical
8.2.10. Summary of Big Pharma Initiatives
9. LIKELY PARTNERS ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Automated and Closed Cell Therapy Processing Systems: Potential Strategic Partners for Cell Therapy Development
9.3.1. Dendritic Cell Therapy
9.3.2. Stem Cell Therapy
9.3.3. T-cell Therapy
9.3.4. Natural Killer Cell Therapy
9.4. Automated and Closed Cell Therapy Processing Systems: Potential Strategic Partners for Cell Therapy Manufacturing
9.4.1. Dendritic Cell Therapy
9.4.2. Stem Cell Therapy
9.4.3. T-cell Therapy
9.4.4. Natural Killer Cell Therapy
10. CASE STUDY: COST BENEFIT ANALYSIS USING PARTIALLY AUTOMATED AND FULLY AUTOMATED SYSTEMS
10.1. Chapter Overview
10.2. Comparative Analysis of Manual, Partially Automated and Fully Automated Cell Processing Systems
10.3. Likely Cost Saving Potential for Kymriah®
10.4. Likely Cost Saving Potential for Yescarata®
10.5. Cost Saving Potential of Fully Automated Processing Systems: Regional Trends
10.6. Concluding Remarks
11. MARKET SIZING AND OPPORTUNITY ANALYSIS
11.1. Chapter Overview
11.2. Key Assumptions and Methodology
11.3. Overall Automated and Closed Cell Therapy Processing Systems Market, Till 2035
11.3.1. Overall Automated and Closed Cell Therapy Processing Systems Market: Distribution by Cell Therapy Processing Step
11.3.1.1. Automated and Closed Cell Therapy Processing Systems Market for Apheresis, Till 2035
11.3.1.2. Automated and Closed Cell Therapy Processing Systems Market for Separation, Till 2035
11.3.1.3. Automated and Closed Cell Therapy Processing Systems Market for Expansion, Till 2035
11.3.1.4. Automated and Closed Cell Therapy Processing Systems Market for Harvest, Till 2035
11.3.1.5. Automated and Closed Cell Therapy Processing Systems Market for Fill / Finish, Till 2035
11.3.1.6. Automated and Closed Cell Therapy Processing Systems Market for Cryopreservation, Till 2035
11.3.1.7. Automated and Closed Cell Therapy Processing Systems Market for Thawing, Till 2035
11.3.2. Automated and Closed Cell Therapy Processing Systems Market: Distribution by Scale of Operation
11.3.2.1. Automated and Closed Cell Therapy Processing Systems Market for Pre-clinical / Clinical Operations, Till 2035
11.3.2.2. Automated and Closed Cell Therapy Processing Systems Market for Commercial Operations, Till 2035
11.3.3. Automated and Closed Cell Therapy Processing Systems Market: Distribution by End User
11.3.3.1. Automated and Closed Cell Therapy Processing Systems Market for Hospitals / Medical Centers / Clinics / Research Institutes / Academic Institutes, Till 2035
11.3.3.2. Automated and Closed Cell Therapy Processing Systems Market for Cell Therapy Manufacturers / Developers, Till 2035
11.3.4. Automated and Closed Cell Therapy Processing Systems Market: Distribution by Key Geographic Regions
11.3.4.1. Automated and Closed Cell Therapy Processing Systems Market in North America, Till 2035
11.3.4.2. Automated and Closed Cell Therapy Processing Systems Market in Europe, Till 2035
11.3.4.3. Automated and Closed Cell Therapy Processing Systems Market in Asia-Pacific, Till 2035
11.3.4.4. Automated and Closed Cell Therapy Processing Systems Market in Latin America (LATAM), Till 2035
11.3.4.5. Automated and Closed Cell Therapy Processing Systems Market in Middle East North America (MENA), Till 2035
12. CONCLUSION
12.1. Chapter Overview
12.2. Key Takeaways
13. INTERVIEW / SURVEY TRANSCRIPT(S)14. APPENDIX 1: TABULATED DATA15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
LIST OF FIGURES
Figure 3.1 Process of Single cell Sequencing
Figure 3.2 Bulk RNA Sequencing versus scRNA Sequencing
Figure 3.3 Applications of Single cell Sequencing
Figure 3.4 Challenges Associated with Single cell Sequencing
Figure 4.1 Single cell Sequencing Service Providers (Industry Players): Distribution by Year of Establishment
Figure 4.2 Single cell Sequencing Service Providers (Industry Players): Distribution by Company Size
Figure 4.3 Single cell Sequencing Service Providers (Industry Players): Distribution by Location of Headquarters
Figure 4.4 Single cell Sequencing Service Providers (Industry Players): Distribution by Sequencing Method Used
Figure 4.5 Single cell Sequencing Service Providers (Industry Players): Distribution by Type of Service Offered
Figure 4.6 Single cell Sequencing Service Providers (Industry Players): Distribution by Type of Library Preparation System Used
Figure 4.7 Single cell Sequencing Service Providers (Industry Players): Distribution by Type of Sequencing System Used
Figure 4.8 Single cell Sequencing Service Providers (Non-Industry Players): Distribution by Location of Organization
Figure 4.9 Single cell Sequencing Service Providers (Non-Industry Players): Distribution by Sequencing Method Used
Figure 4.10 Single cell Sequencing Service Providers (Non-Industry Players): Distribution by Type of Service Offered
Figure 4.11 Single cell Sequencing Service Providers (Non-Industry Players): Distribution by Type of Library Preparation System Used
Figure 4.12 Single cell Sequencing Service Providers (Non-Industry Players): Distribution by Type of Sequencing System Used
Figure 5.1 Single cell Sequencing Workflow Instruments: Distribution by Targeted Nucleic Acid
Figure 5.2 Single cell Sequencing Workflow Instruments: Distribution by Type of Application
Figure 5.3 Single cell Sequencing Workflow Instruments: Distribution by Throughput
Figure 5.4 Single cell Sequencing Workflow Instrument Providers: Distribution by Year of Establishment
Figure 5.5 Single cell Sequencing Workflow Instrument Providers: Distribution by Company Size
Figure 5.6 Single cell Sequencing Workflow Instrument Providers: Distribution by Location of Headquarters
Figure 5.7 Single cell Sequencing Instruments: Distribution by Type of Application
Figure 5.8 Single cell Sequencing Instruments: Distribution by Maximum Output
Figure 5.9 Single cell Sequencing Instruments: Distribution by Maximum Read Length
Figure 5.10 Single cell Sequencing Instruments: Distribution by System Efficiency
Figure 5.11 Single cell Sequencing Instruments: Distribution by Sequencing Chemistry
Figure 5.12 Single cell Sequencing Instrument Providers: Distribution by Year of Establishment
Figure 5.13 Single cell Sequencing Instrument Providers: Distribution by Company Size
Figure 5.14 Single cell Sequencing Instrument Providers: Distribution by Location of Headquarters
Figure 6.1 Platform Competitiveness Analysis: Single cell Workflow Instruments (Peer Group I)
Figure 6.2 Platform Competitiveness Analysis: Single cell Workflow Instruments (Peer Group II)
Figure 6.3 Platform Competitiveness Analysis: Single cell Sequencing Instruments (Peer Group I)
Figure 6.4 Platform Competitiveness Analysis: Single cell Sequencing Instruments (Peer Group II)
Figure 8.1 10x Genomics: Annual Revenues, Since 2017 (USD Million)
Figure 8.2 Fluidigm: Annual Revenues, Since 2015 (USD Million)
Figure 8.3 Illumina: Annual Revenues, Since 2013 (USD Billion)
Figure 8.4 Illumina: Sequencing Systems Portfolio
Figure 8.5 Oxford Nanopore Technologies: Sequencing Systems Portfolio
Figure 9.1 Patent Analysis: Distribution by Patent Type
Figure 9.2 Patent Analysis: Cumulative Distribution by Publication Year, Since 2015
Figure 9.3 Patent Analysis: Distribution by Geographical Location and Publication Year Since 2015
Figure 9.4 Patent Analysis: Distribution by Patent Type and Publication Year
Figure 9.5 Patent Analysis: Distribution by Geographical Location
Figure 9.6 Patent Analysis: Distribution by Jurisdiction
Figure 9.7 Patent Analysis: Distribution by CPC Symbols
Figure 9.8 Patent Analysis: Emerging Focus Areas
Figure 9.9 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant Since 2015
Figure 9.10 Leading Players: Distribution by Number of Patents
Figure 9.11 Patent Analysis (Leading Players): Benchmarking by Patent Characteristics (CPC Classifications)
Figure 9.12 Patent Analysis: Benchmarking by International Patents
Figure 9.13 Patent Analysis: Distribution of Patents by Geographical Region and Patent Type
Figure 9.14 Single cell Sequencing: Age of Patents
Figure 9.15 Patent Analysis: Valuation Analysis
Figure 10.1 Academic Grant Analysis: Cumulative Year-wise Trend, Since 2016
Figure 10.2 Academic Grant Analysis: Cumulative Year-Wise Distribution by Grant Amount (USD Million)
Figure 10.3 Academic Grant Analysis: Distribution by Focus Area
Figure 10.4 Academic Grant Analysis: Distribution by Activity Code
Figure 10.5 Academic Grant Analysis: Distribution by Support Period
Figure 10.6 Academic Grant Analysis: Distribution by Funding Mechanism
Figure 10.7 Academic Grant Analysis: Distribution of Funding Institute Center by Support Year and Number of Grants
Figure 10.8 Academic Grant Analysis: Distribution by Type of Recipient Organization
Figure 10.9 Popular Recipient Organizations: Distribution across States in the US
Figure 10.10 Popular Recipient Organizations: Distribution by Number of Grants
Figure 10.11 Popular Recipient Organizations: Distribution by Amount Awarded (USD Million)
Figure 10.12 Prominent Program Officers: Distribution by Number of Grants
Figure 11.1 Recent Partnerships: Distribution by Year of Partnership
Figure 11.2 Recent Partnerships: Distribution by Type of Agreement
Figure 11.3 Recent Partnerships: Distribution by Focus Area of Partnership
Figure 11.4 Recent Partnerships: Regional Distribution
Figure 11.5 Recent Investments: Distribution by Year of Funding
Figure 11.6 Recent Investments: Distribution by Type of Funding
Figure 11.7 Recent Investments: Distribution by Amount Invested (USD Million)
Figure 11.8 Most Active Players: Distribution by Amount Invested
Figure 11.9 Most Active Investors: Distribution by Number of Funding Instances
Figure 11.10 Recent Product Launches: Distribution by Year of Product Launch
Figure 11.11 Recent Product Launches: Distribution by Type of Product
Figure 11.12 Recent Product Launches: Distribution by Focus Area
Figure 11.13 Most Active Players: Distribution by Number of Product Launches
Figure 12.1 Overall Single cell Sequencing Services and Technologies Market Opportunity, Till 2030 (USD Million)
Figure 12.2 Single cell Sequencing Services and Technologies Market Opportunity Across Key Market Segments (USD Million)
Figure 12.3 Single cell Sequencing Services and Technologies Market Opportunity: Distribution by Type of System (USD Million)
Figure 12.4 Single cell Sequencing Services and Technologies Market Opportunity: Distribution by End-User (USD Million)
Figure 12.5 Single cell Sequencing Services and Technologies Market Opportunity: Distribution by Area of Application (USD Million)
Figure 12.6 Single cell Sequencing Services and Technologies Market Opportunity: Geographical Distribution (USD Million)
Figure 12.7 Single cell Sequencing Services and Technologies Market Opportunity in North America, Till 2030 (USD Million)
Figure 12.8 Single cell Sequencing Services and Technologies Market Opportunity in North America: Share of Service Providers, Till 2030 (USD Million)
Figure 12.9 Single cell Sequencing Services and Technologies Market Opportunity in North America: Share of Technology Providers, Till 2030 (USD Million)
Figure 12.10 Single cell Sequencing Services and Technologies Market Opportunity in North America: Share of Academic and Research Institutions, Till 2030 (USD Million)
Figure 12.11 Single cell Sequencing Services and Technologies Market Opportunity in North America: Share of Pharmaceutical Companies, Till 2030 (USD Million)
Figure 12.12 Single cell Sequencing Services and Technologies Market Opportunity in North America: Share of Other End-Users, Till 2030 (USD Million)
Figure 12.13 Single cell Sequencing Services and Technologies Market Opportunity in North America: Share of Diagnostics, Till 2030 (USD Million)
Figure 12.14 Single cell Sequencing Services and Technologies Market Opportunity in North America: Share of Drug Discovery, Till 2030 (USD Million)
Figure 12.15 Single cell Sequencing Services and Technologies Market Opportunity in North America: Share of Precision Medicine, Till 2030 (USD Million)
Figure 12.16 Single cell Sequencing Services and Technologies Market Opportunity in North America: Share of Other Applications, Till 2030 (USD Million)
Figure 12.17 Single cell Sequencing Services and Technologies Market Opportunity in Europe, Till 2030 (USD Million)
Figure 12.18 Single cell Sequencing Services and Technologies Market Opportunity in Europe: Share of Service Providers, Till 2030 (USD Million)
Figure 12.19 Single cell Sequencing Services and Technologies Market Opportunity in Europe: Share of Technology Providers, Till 2030 (USD Million)
Figure 12.20 Single cell Sequencing Services and Technologies Market Opportunity in Europe: Share of Academic and Research Institutions, Till 2030 (USD Million)
Figure 12.21 Single cell Sequencing Services and Technologies Market Opportunity in Europe: Share of Pharmaceutical Companies, Till 2030 (USD Million)
Figure 12.22 Single cell Sequencing Services and Technologies Market Opportunity in Europe: Share of Other End-Users, Till 2030 (USD Million)
Figure 12.23 Single cell Sequencing Services and Technologies Market Opportunity in Europe: Share of Diagnostics, Till 2030 (USD Million)
Figure 12.24 Single cell Sequencing Services and Technologies Market Opportunity in Europe: Share of Drug Discovery, Till 2030 (USD Million)
Figure 12.25 Single cell Sequencing Services and Technologies Market Opportunity in Europe: Share of Precision Medicine, Till 2030 (USD Million)
Figure 12.26 Single cell Sequencing Services and Technologies Market Opportunity in Europe: Share of Other Applications, Till 2030 (USD Million)
Figure 12.27 Single cell Sequencing Services and Technologies Market Opportunity in Asia-Pacific, Till 2030 (USD Million)
Figure 12.28 Single cell Sequencing services and Technologies Market Opportunity in Asia-Pacific: Share of Service Providers, Till 2030 (USD Million)
Figure 12.29 Single cell Sequencing services and Technologies Market Opportunity in Asia-Pacific: Share of Technology Providers, Till 2030 (USD Million)
Figure 12.30 Single cell Sequencing services and Technologies Market Opportunity in Asia-Pacific: Share of Academic and Research Institutions, Till 2030 (USD Million)
Figure 12.31 Single cell Sequencing Services and Technologies Market Opportunity in Asia-Pacific: Share of Pharmaceutical Companies, Till 2030 (USD Million)
Figure 12.32 Single cell Sequencing Services and Technologies Market Opportunity in Asia-Pacific: Share of Other End-Users, Till 2030 (USD Million)
Figure 12.33 Single cell Sequencing Services and Technologies Market Opportunity in Asia-Pacific: Share of Diagnostics, Till 2030 (USD Million)
Figure 12.34 Single cell Sequencing Services and Technologies Market Opportunity in Asia-Pacific: Share of Drug Discovery, Till 2030 (USD Million)
Figure 12.35 Single cell Sequencing Services and Technologies Market Opportunity in Asia-Pacific: Share of Precision Medicine, Till 2030 (USD Million)
Figure 12.36 Single cell Sequencing Services and Technologies Market Opportunity in Asia-Pacific: Share of Other Applications, Till 2030 (USD Million)
Figure 12.37 Single cell Sequencing Services and Technologies Market Opportunity in Rest of the World, Till 2030 (USD Million)
Figure 12.38 Single cell Sequencing Services and Technologies Market Opportunity in Rest of the World: Share of Service Providers, Till 2030 (USD Million)
Figure 12.39 Single cell Sequencing Services and Technologies Market Opportunity in Rest of the World: Share of Technology Providers, Till 2030 (USD Million)
Figure 12.40 Single cell Sequencing Services and Technologies Market Opportunity in Rest of the World: Share of Academic and Research Institutions, Till 2030 (USD Million)
Figure 12.41 Single cell Sequencing Services and Technologies Market Opportunity in Rest of the World: Share of Pharmaceutical Companies, Till 2030 (USD Million)
Figure 12.42 Single cell Sequencing Services and Technologies Market Opportunity in Rest of the World: Share of Other End-Users, Till 2030 (USD Million)
Figure 12.43 Single cell Sequencing Services and Technologies Market Opportunity in Rest of the World: Share of Diagnostics, Till 2030 (USD Million)
Figure 12.44 Single cell Sequencing Services and Technologies Market Opportunity in Rest of the World: Share of Drug Discovery, Till 2030 (USD Million)
Figure 12.45 Single cell Sequencing Services and Technologies Market Opportunity in Rest of the World: Share of Precision Medicine, Till 2030 (USD Million)
Figure 12.46 Single cell Sequencing Services and Technologies Market Opportunity in Rest of the World: Share of Other Applications, Till 2030 (USD Million)
LIST OF TABLES
Table 3.1 Comparison of Bulk RNA Sequencing and scRNA Sequencing
Table 4.1 Single cell Sequencing Service Providers: List of Industry Players
Table 4.2 Single cell Sequencing Service Providers (Industry Players): Information on Sequencing Method, Turn Around Time and Sample Used
Table 4.3 Single cell Sequencing Service Providers (Industry Players): Information on Type of Service Offered, Library Preparation System Used and Sequencing System Used
Table 4.4 Single cell Sequencing Providers: List of Non-Industry Players
Table 4.5 Single cell Sequencing Service Providers (Non-Industry Players): Information on Sequencing Method Used, Turn Around Time and Price of Services
Table 4.6 Single cell Sequencing Service Providers (Non-Industry Players): Information on Type of Service Offered, Library Preparation System Used and Sequencing System Used
Table 4.7 Additional List of Companies
Table 5.1 Single cell Sequencing Workflow Instruments: Information on Name of Developer, Target Nucleic Acid and System Throughput
Table 5.2 Single cell Sequencing Workflow Instruments: Information on Type of Application and Analytical Software Used
Table 5.3 List of Single cell Sequencing Workflow Instrument Providers
Table 5.4 Single cell Sequencing Instruments: Information on Type of Application, Run Time, Maximum Output and Output Range
Table 5.5 Single cell Sequencing Instruments: Information on Maximum Reads per Run, Reads per Run, Maximum Read Length, Maximum Quality Score, Sequencing Chemistry and Cost of Instrument
Table 5.6 List of Single cell Sequencing Instrument Providers
Table 7.1 Single cell Sequencing Service Providers: List of Profiled Companies
Table 7.2 Active Motif: Company Snapshot
Table 7.3 Admera Health: Company Snapshot
Table 7.4 Admera Health: Recent Developments and Future Outlook
Table 7.5 Annoroad Genomics: Company Snapshot
Table 7.6 Annoroad Genomics: Recent Developments and Future Outlook
Table 7.7 BGI Genomics: Company Snapshot
Table 7.8 BGI Genomics: Recent Developments and Future Outlook
Table 7.9 CD Genomics: Company Snapshot
Table 7.10 CD Genomics: Recent Developments and Future Outlook
Table 7.11 MedGenome: Company Snapshot
Table 7.12 MedGenome: Recent Developments and Future Outlook
Table 7.13 Quick Biology: Company Snapshot
Table 7.14 Quick Biology: Recent Developments and Future Outlook
Table 7.15 SingulOmics: Company Snapshot
Table 8.1 10x Genomics: Company Snapshot
Table 8.2 10x Genomics: Recent Developments and Future Outlook
Table 8.3 Cell Microsystems: Company Snapshot
Table 8.4 Fluidigm: Company Snapshot
Table 8.5 Fluidigm: Recent Developments and Future Outlook
Table 8.6 Illumina: Company Snapshot
Table 8.7 Illumina: Recent Developments and Future Outlook
Table 8.8 Mission Bio: Company Snapshot
Table 8.9 Mission Bio: Recent Developments and Future Outlook
Table 8.10 Oxford Nanopore Technologies: Company Snapshot
Table 8.11 Oxford Nanopore Technologies: Recent Developments and Future Outlook
Table 9.1 Patent Analysis: CPC Symbols
Table 9.2 Patent Analysis: Most Popular CPC Symbols
Table 9.3 Patent Analysis: List of Top 10 CPC Symbols
Table 9.4 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 9.5 Patent Analysis: List of Relatively Higher Value Patents
Table 15.1 Single cell Sequencing Service Providers (Industry Players): Distribution by Year of Establishment
Table 15.2 Single cell Sequencing Service Providers (Industry Players): Distribution by Company Size
Table 15.3 Single cell Sequencing Service Providers (Industry Players): Distribution by Location of Headquarters
Table 15.4 Single cell Sequencing Service Providers (Industry Players): Distribution by Sequencing Method Used
Table 15.5 Single cell Sequencing Service Providers (Industry Players): Distribution by Type of Service Offered
Table 15.6 Single cell Sequencing Service Providers (Industry Players): Distribution by Type of Library Preparation System Used
Table 15.7 Single cell Sequencing Service Providers (Industry Players): Distribution by Type of Sequencing System Used
Table 15.8 Single cell Sequencing Service Providers (Non-Industry Players): Distribution by Location of Organization
Table 15.9 Single cell Sequencing Service Providers (Non-Industry Players): Distribution by Sequencing Method Used
Table 15.10 Single cell Sequencing Service Providers (Non-Industry Players): Distribution by Types of Service Offered
Table 15.11 Single cell Sequencing Service Providers (Non-Industry Players): Distribution by Type of Library Preparation System Used
Table 15.12 Single cell Sequencing Service Providers (Non-Industry Players): Distribution by Type of Sequencing System Used
Table 15.13 Single cell Sequencing Workflow Instruments: Distribution by Target Nucleic Acid
Table 15.14 Single cell Sequencing Workflow Instruments: Distribution by Type of Application
Table 15.15 Single cell Sequencing Workflow Instruments: Distribution by Throughput
Table 15.16 Single cell Sequencing Workflow Instrument Providers: Distribution by Year of Establishment
Table 15.17 Single cell Sequencing Workflow Instrument Providers: Distribution by Company Size
Table 15.18 Single cell Sequencing Workflow Instrument Providers: Distribution by Location of Headquarters
Table 15.19 Single cell Sequencing Instruments: Distribution by Type of Application
Table 15.20 Single cell Sequencing Instruments: Distribution by Maximum Output
Table 15.21 Single cell Sequencing Instruments: Distribution by Maximum Read Length
Table 15.22 Single cell Sequencing Instruments: Distribution by System Efficiency
Table 15.23 Single cell Sequencing Instruments: Distribution by Sequencing Chemistry
Table 15.24 Single cell Sequencing Instrument Providers: Distribution by Year of Establishment
Table 15.25 Single cell Sequencing Instrument Providers: Distribution by Company Size
Table 15.26 Single cell Sequencing Instrument Providers: Distribution by Location of Headquarters
Table 15.27 10x Genomics: Annual Revenues, Since 2017 (USD Million)
Table 15.28 Fluidigm: Annual Revenues, Since 2015 (USD Million)
Table 15.29 Illumina: Annual Revenues, Since 2013 (USD Billion)
Table 15.30 Patent Analysis: Distribution by Patent Type
Table 15.31 Patent Analysis: Cumulative Distribution by Publication Year, Since 2015
Table 15.32 Patent Analysis: Distribution by Geographical Location and Publication Year Since 2015
Table 15.33 Patent Analysis: Distribution by Patent Type and Publication Year
Table 15.34 Patent Analysis: Distribution by Geographical Location
Table 15.35 Patent Analysis: Distribution by Jurisdiction
Table 15.36 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant Since 2015
Table 15.37 Leading Players: Distribution by Number of Patents
Table 15.38 Patent Analysis: Distribution of Patents by Geographical Region and Patent Type
Table 15.39 Single cell Sequencing: Age of Patents
Table 15.40 Academic Grant Analysis: Cumulative Year-wise Trend, Since 2016
Table 15.41 Academic Grant Analysis: Cumulative Year-Wise Distribution by Grant Amount (USD Million)
Table 15.42 Academic Grant Analysis: Distribution by Activity Codes
Table 15.43 Academic Grant Analysis: Distribution by Support Period
Table 15.44 Academic Grant Analysis: Distribution by Funding Mechanism
Table 15.45 Academic Grant Analysis: Distribution by Type of Recipient Organization
Table 15.46 Popular Recipient Organizations: Distribution by Number of Grants
Table 15.47 Popular Recipient Organizations: Distribution by Amount Awarded (USD Million)
Table 15.48 Prominent Program Officers: Distribution by Number of Grants
Table 15.49 Recent Partnerships: Distribution by Year of Partnership
Table 15.50 Recent Partnerships: Distribution by Type of Agreement
Table 15.51 Recent Partnerships: Distribution by Focus Area of Partnership
Table 15.52 Recent Partnerships: Regional Distribution
Table 15.53 Recent Investments: Distribution by Year of Funding
Table 15.54 Recent Investments: Distribution by Type of Funding
Table 15.55 Recent Investments: Distribution by Amount Invested (USD Million)
Table 15.56 Most Active Players: Distribution by Amount Invested
Table 15.57 Most Active Investors: Distribution by Number of Funding Instances
Table 15.58 Recent Product Launches: Distribution by Year of Product Launch
Table 15.59 Recent Product Launches: Distribution by Type of Product
Table 15.60 Recent Product Launches: Distribution by Focus Area
Table 15.61 Most Active Players: Distribution by Number of Product Launches
Table 15.62 Overall Single cell Sequencing Services and Technologies Market Opportunity, Conservative, Base and Optimistic Scenario, Till 2030 (USD Million)
Table 15.63 Single cell Sequencing Services and Technologies Market Opportunity Across Key Market Segments (USD Million)
Table 15.64 Single cell Sequencing Services and Technologies Market Opportunity: Distribution by Type of System (USD Million)
Table 15.65 Single cell Sequencing Services and Technologies Market Opportunity: Distribution by End-User (USD Million)
Table 15.66 Single cell Sequencing Services and Technologies Market Opportunity: Distribution by Area of Application (USD Million)
Table 15.67 Single cell Sequencing Services and Technologies Market Opportunity: Geographical Distribution (USD Million)
Table 15.68 Single cell Sequencing Services and Technologies Market Opportunity in North America, Conservative, Base and Optimistic Scenario, Till 2030 (USD Million)
Table 15.69 Single cell Sequencing services and Technologies Market Opportunity in North America: Share of Service Providers, Till 2030 (USD Million)
Table 15.70 Single cell Sequencing services and Technologies Market Opportunity in North America: Share of Technology Providers, Till 2030 (USD Million)
Table 15.71 Single cell Sequencing services and Technologies Market Opportunity in North America: Share of Academic and Research Institutions, Till 2030 (USD Million)
Table 15.72 Single cell Sequencing services and Technologies Market Opportunity in North America: Share of Pharmaceutical Companies, Till 2030 (USD Million)
Table 15.73 Single cell Sequencing services and Technologies Market Opportunity in North America: Share of Other End-Users, Till 2030 (USD Million)
Table 15.74 Single cell Sequencing services and Technologies Market Opportunity in North America: Share of Diagnostics, Till 2030 (USD Million)
Table 15.75 Single cell Sequencing services and Technologies Market Opportunity in North America: Share of Drug Discovery, Till 2030 (USD Million)
Table 15.76 Single cell Sequencing services and Technologies Market Opportunity in North America: Share of Precision Medicine, Till 2030 (USD Million)
Table 15.77 Single cell Sequencing services and Technologies Market Opportunity in North America: Share of Other Applications, Till 2030 (USD Million)
Table 15.78 Single cell Sequencing Services and Technologies Market Opportunity in Europe, Conservative, Base and Optimistic Scenario, Till 2030 (USD Million)
Table 15.79 Single cell Sequencing services and Technologies Market Opportunity in Europe: Share of Service Providers, Till 2030 (USD Million)
Table 15.80 Single cell Sequencing services and Technologies Market Opportunity in Europe: Share of Technology Providers, Till 2030 (USD Million)
Table 15.81 Single cell Sequencing services and Technologies Market Opportunity in Europe: Share of Academic and Research Institutions, Till 2030 (USD Million)
Table 15.82 Single cell Sequencing services and Technologies Market Opportunity in Europe: Share of Pharmaceutical Companies, Till 2030 (USD Million)
Table 15.83 Single cell Sequencing services and Technologies Market Opportunity in Europe: Share of Other End-Users, Till 2030 (USD Million)
Table 15.84 Single cell Sequencing services and Technologies Market Opportunity in Europe: Share of Diagnostics, Till 2030 (USD Million)
Table 15.85 Single cell Sequencing services and Technologies Market Opportunity in Europe: Share of Drug Discovery, Till 2030 (USD Million)
Table 15.86 Single cell Sequencing services and Technologies Market Opportunity in Europe: Share of Precision Medicine, Till 2030 (USD Million)
Table 15.87 Single cell Sequencing services and Technologies Market Opportunity in Europe: Share of Other Applications, Till 2030 (USD Million)
Table 15.88 Single cell Sequencing Services and Technologies Market Opportunity in Asia-Pacific, Conservative, Base and Optimistic Scenario, Till 2030 (USD Million)
Table 15.89 Single cell Sequencing services and Technologies Market Opportunity in Asia-Pacific: Share of Service Providers, Till 2030 (USD Million)
Table 15.90 Single cell Sequencing services and Technologies Market Opportunity in Asia-Pacific: Share of Technology Providers, Till 2030 (USD Million)
Table 15.91 Single cell Sequencing services and Technologies Market Opportunity in Asia-Pacific: Share of Academic and Research Institutions, Till 2030 (USD Million)
Table 15.92 Single cell Sequencing services and Technologies Market Opportunity in Asia-Pacific: Share of Pharmaceutical Companies, Till 2030 (USD Million)
Table 15.93 Single cell Sequencing services and Technologies Market Opportunity in Asia-Pacific: Share of Other End-Users, Till 2030 (USD Million)
Table 15.94 Single cell Sequencing services and Technologies Market Opportunity in Asia-Pacific: Share of Diagnostics, Till 2030 (USD Million)
Table 15.95 Single cell Sequencing services and Technologies Market Opportunity in Asia-Pacific: Share of Drug Discovery, Till 2030 (USD Million)
Table 15.96 Single cell Sequencing services and Technologies Market Opportunity in Asia-Pacific: Share of Precision Medicine, Till 2030 (USD Million)
Table 15.97 Single cell Sequencing services and Technologies Market Opportunity in Asia-Pacific: Share of Other Applications, Till 2030 (USD Million)
Table 15.98 Single cell Sequencing Services and Technologies Market Opportunity in Rest of the World, Conservative, Base and Optimistic Scenario, Till 2030 (USD Million)
Table 15.99 Single cell Sequencing services and Technologies Market Opportunity in Rest of the World: Share of Service Providers, Till 2030 (USD Million)
Table 15.100 Single cell Sequencing services and Technologies Market Opportunity in Rest of the World: Share of Technology Providers, Till 2030 (USD Million)
Table 15.101 Single cell Sequencing services and Technologies Market Opportunity in Rest of the World: Share of Academic and Research Institutions, Till 2030 (USD Million)
Table 15.102 Single cell Sequencing services and Technologies Market Opportunity in Rest of the World: Share of Pharmaceutical Companies, Till 2030 (USD Million)
Table 15.103 Single cell Sequencing services and Technologies Market Opportunity in Rest of the World: Share of Other End-Users, Till 2030 (USD Million)
Table 15.104 Single cell Sequencing services and Technologies Market Opportunity in Rest of the World: Share of Diagnostics, Till 2030 (USD Million)
Table 15.105 Single cell Sequencing services and Technologies Market Opportunity in Rest of the World: Share of Drug Discovery, Till 2030 (USD Million)
Table 15.106 Single cell Sequencing services and Technologies Market Opportunity in Rest of the World: Share of Precision Medicine, Till 2030 (USD Million)
Table 15.107 Single cell Sequencing services and Technologies Market Opportunity in Rest of the World: Share of Other Applications, Till 2030 (USD Million)

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • 4D Molecular Therapeutics
  • 53Biologics
  • AavantiBios
  • Abbott
  • AbbVie
  • Abeona Therapeutics
  • Abintus Bio
  • Accinov (acquired by Advanced BioScience Laboratories)
  • Acucela
  • AcuraBio
  • Adaptimmune Therapeutics
  • AdaptVac
  • Addgene
  • Aduro Biotech
  • Advaccine
  • Advanced BioScience Laboratories
  • Advanced Biotherapeutics Consulting
  • Advantagene
  • Advaxis
  • Advent
  • Adverum Biotechnologies (formerly known as Avalanche Biotechnologies)
  • Aevitas Therapeutics (a subsidiary of Fortress Biotech)
  • AffyImmune Therapeutics
  • AffyXel
  • AGC Biologics
  • Agilent Technologies
  • Agilis Biotherapeutics (acquired by PTC Therapeutics)
  • Ajinomoto Bio-Pharma Services
  • Akdeniz University
  • Akron Biotech
  • Albumedix
  • Aldevron
  • Allele Biotechnology
  • Allergan
  • Allife Medicine
  • Allogene Therapeutics
  • Alma Bio Therapeutics
  • AlphaVax
  • ALSTEM
  • Althea Technologies
  • Altimmune
  • Altor BioScience
  • Altruist Biologics
  • American Gene Technologies
  • Amgen
  • Amicus Therapeutics
  • Ampersand Capital Partners
  • AMSBIO
  • Amsterdam BioTherapeutics Unit
  • Amsterdam Molecular Therapeutics (acquired by uniQure)
  • Anaeropharma Science
  • Andelyn Biosciences
  • Anemocyte
  • AnGes
  • Angionetics
  • ANLBIO
  • Annapurna Therapeutics (acquired by Avalanche Biotechnologies)
  • apceth Biopharma (subsidiary of Hitachi Chemical)
  • Applied Biological Materials
  • Applied Genetic Technologies (AGTC)
  • Applied StemCell
  • Applied Viromics
  • Arcellx
  • ArcticZymes Technologies
  • Areta International
  • Arranta Bio (acquired by Recipharm)
  • Aruvant Sciences
  • ASC Therapeutics
  • AskBio
  • Asklepios BioPharmaceutical
  • Astellas Pharma
  • AstraZeneca
  • Atara Biotherapeutics
  • Atlantic Bio GMP (a subsidiary of Atlanpole Biotherapies)
  • Atsena Therapeutics
  • Audentes Therapeutics (acquired by Astella Pharma)
  • Augusta University
  • Aurigene Pharmaceutical Services
  • Aurora Biopharma
  • Autolus Therapeutics
  • Avantor
  • Avecia Biologics
  • Avid Bioservices
  • AVROBIO
  • Axovant Gene Therapies
  • Bamboo Therapeutics
  • Batavia Biosciences
  • Baylor College of Medicine
  • BCM Families Foundation
  • Beacon Biotherapeutics
  • Beam Therapeutics
  • Beckman Research Institute
  • Beijing Biohealthcare Biotechnology
  • Beijing Doing Biomedical
  • Beijing Hetang Shenghua Medical Technology
  • Beijing HuiNengAn Biotech
  • Beijing Immunochina Medical Science & Technology
  • Beijing Mario Biotech
  • Beijing Sanwater Biological Technology
  • Bellicum Pharmaceuticals
  • Benitec Biopharma
  • BIA Separations (acquired by Sartorius)
  • Bioceltech Therapeutics
  • BioCentriq (acquired by GC)
  • BioCina
  • Biogen
  • Bio-Gene Technology
  • BioInvent International
  • Biological E.
  • BioMarin Pharmaceuticals
  • Biomay
  • Biomiga
  • Bionic Sight
  • BioNTech Innovative Manufacturing Service (a subsidiary of BioNTech)
  • Bio-Rad Laboratories
  • BioReliance (a subsidiary of Merck KGaA)
  • Bio-Synthesis
  • BioVec Pharma
  • Bioverativ
  • Biovian
  • BioVision
  • Blue Sky BioServices (a subsidiary of LakePharma)
  • bluebird bio (formerly known as Genetix Pharmaceuticals)
  • BMS
  • Boehringer Ingelheim BioXcellence
  • BoYuan RunSheng Pharma
  • Brain Neurotherapy Bio
  • Brammer Bio (acquired by Thermo Fisher Scientific)
  • Brazilian Biosciences National Laboratory (LNBio)
  • Bristol Myers Squibb
  • Cabaletta Bio
  • Caltech
  • Cambridge Gene Therapy
  • Candel Therapeutics
  • Capsugel
  • Carina Biotech
  • Carmine Therapeutics
  • CARsgen Therapeutics
  • Cartesian Therapeutics
  • Casey Eye Institute
  • Castle Creek Biosciences
  • Catalent Biologics
  • Celgene
  • Cell and Gene Therapy Catapult
  • Cell Biolabs
  • Cellectis
  • CellGenTech
  • Cellular Biomedicine Group
  • CellVec
  • Celonic
  • Celsion
  • Celyad Oncology
  • Center for Breakthrough Medicines
  • Centre for Commercialization of Regenerative Medicine
  • Centre for Process Innovation
  • Cepham Life Sciences
  • CEVEC Pharmaceuticals
  • CG Oncology
  • Charles River Laboratories
  • Children’s Medical Research Institute (CMRI)
  • Children's Hospital of Philadelphia
  • China Immunotech Biotechnology
  • Choroideremia Research Foundation
  • Cincinnati Children's Hospital Medical Center
  • City of Hope
  • Clean Cells
  • CLINO
  • Cognate BioServices
  • CoJourney
  • CombiGene
  • Copernicus Therapeutics
  • Cornell University
  • Creative Biogene
  • Creative Biolabs
  • CSL Behring
  • Curia
  • Cytiva (formerly known as GE Healthcare Life Sciences)
  • CytoMed Therapeutics
  • Cytovance Biologics
  • Daiichi Sankyo
  • Decibel
  • Delphi Genetics
  • Denali Therapeutics
  • Department of Cell and Chemical Biology, Leiden University Medical Center
  • DiNAMIQS
  • DiNAQOR
  • DNAtrix
  • Duke University
  • Durham
  • Dyno Therapeutics
  • Editas Medicine
  • ElevateBio
  • Elixirgen Scientific
  • Emendo Biotherapeutics
  • Emergent BioSolutions
  • Emory University School of Medicine
  • enGene
  • Epeius Biotechnologies
  • Errant Gene Therapeutics
  • Erytech Pharma
  • Esco Aster
  • Esteve
  • eTheRNA immunotherapies
  • EUFETS
  • Eureka Biotechnology
  • Eurofins Genomics
  • Eurofins Scientific
  • ExcellGene
  • Exothera
  • Expression Therapeutics
  • Eyevensys
  • Fate Therapeutics
  • FerGene
  • FIMA
  • FinVector (formerly known as Ark Therapeutics)
  • Five Prime Therapeutics
  • Flash Therapeutics
  • Flexion Therapeutics
  • Florida Biologix
  • Forecyte Bio
  • Forge Biologics
  • Formula Pharmaceuticals
  • Fortress Biotech
  • Fosun Pharma
  • Foundation Fighting Blindness
  • Fraunhofer Institute for Toxicology and Experimental Medicine
  • Freeline Therapeutics
  • FUJIFILM Diosynth Biotechnologies
  • Fundamenta Therapeutics
  • G-CON Manufacturing
  • GE Healthcare Life Sciences
  • GEG Tech
  • Genable Technologies
  • GeneCopoeia
  • GeneCure Biotechnologies
  • GeneDetect
  • GeneImmune Biotechnology
  • Genelux
  • GeneMedicine
  • Genenta Science
  • GeneOne Life Science
  • Genethon
  • GENEWIZ
  • Genexine
  • Genezen Laboratories
  • GenIbet Biopharmaceuticals
  • Genopis (acquired by Wacker Biotech)
  • Genovac
  • Genprex
  • GenScript
  • GenSight Biologics
  • GenVec
  • Gen-X
  • Genzyme
  • GeoVax Labs
  • GIGA
  • GlaxoSmithKline
  • Gracell Biotechnologies
  • Gradalis
  • Green Cross LabCell
  • Grousbeck Gene Therapy Center
  • Guangdong Xiangxue Precision Medical Technology
  • Guangdong Zhaotai InVivo Biomedicine
  • Guangzhou Anjie Biomedical Technology
  • Guangzhou FineImmune Biotechnology
  • Gyroscope Therapeutics
  • Hadassah Medical Organization
  • HaemaLogiX
  • HALIX
  • Handl Therapeutics
  • Hanmi Bio Plant (a subsidiary of Hanmi Pharm)
  • Harvard Gene Therapy Initiative
  • Hebei Senlang Biotechnology
  • Heidelberg University Hospital
  • Helixmith
  • Hemera Biosciences
  • Henan Hualong Biotechnology
  • Herantis Pharma
  • Hitachi Chemical Advanced Therapeutics Solutions
  • Holostem Terapie Avanzate
  • Homology Medicines
  • Hong Kong Institute of Biotechnology
  • Hookipa Biotech
  • HORAMA
  • Hrain Biotechnology
  • Huadao biomedical
  • Huapont Life Sciences
  • Human Stem Cells Institute
  • Hunan Zhaotai Yongren Medical Innovation
  • Icahn School of Medicine at Mount Sinai
  • iCAR Bio Therapeutics
  • iCarTAB BioMed
  • iCell Gene Therapeutics
  • ID Pharma (formerly known as DNAVEC)
  • IDT Biologika
  • Ilya Pharma
  • Immatics
  • Immune Design
  • Immune Technology
  • Immunocore
  • Immunomic Therapeutics
  • Imperial Innovations
  • Imperial Innovations
  • Indiana University
  • Innovative Cellular Therapeutics
  • InnovaVector
  • INOVIO Pharmaceuticals
  • InProTher
  • Institute for Bioengineering of Catalonia
  • Institute of Medical Science Research Hospital
  • Institute of Translational Health Sciences
  • International AIDS Vaccine Initiative (IAVI)
  • InvivoGen
  • IPPOX Foundation
  • IQVIA (formerly known as QuintilesIMS)
  • Iveric Bio
  • JAFRAL Biosolutions
  • Jansen Pharmaceuticals
  • Jiangsu Puxin Biomedicine
  • Juno Therapeutics
  • Juventas Cell Therapy
  • JW Therapeutics
  • KAEDI
  • Kaneka Eurogentec
  • Karolinska Institute
  • Karolinska University Hospital
  • Kavli Institute for Systems Neuroscience
  • Kecellitics Biotech
  • King's College London
  • Kite Pharma (a subsidiary of Gilead Sciences)
  • KMD Bioscience
  • Kobe Biomedical Innovation Cluster
  • Kolon TissueGene
  • Kriya Therapeutics
  • Krystal Biotech
  • Kuur Therapeutics
  • Laboratory of Digital Sciences of Nantes
  • LakePharma (acquired by Curia)
  • Legend Biotech
  • Leiden University Medical Centre
  • Lentigen Technology
  • Leucid Bio
  • Leukocare
  • Leuven Viral Vector Core (LVVC)
  • Lexeo
  • LEXEO Therapeutics
  • Lion TCR
  • Lipigon Pharmaceuticals
  • LNBio
  • LogicBio Therapeutics
  • LOKA Biosciences
  • Lokon Pharma
  • Lonza
  • Louisiana State University School of Veterinary Medicine
  • Luina Bio
  • Luminous BioSciences
  • Lund University
  • Lysogene
  • Magee-Womens Research Institute
  • Maine Medical Center Research Institute (MMCRI)
  • MaineHealth Institute for Research
  • MaineHealth Institute for Research (MHIR)
  • MangoGen Pharma
  • Marino Biotechnology
  • Mass Biologics
  • Massachusetts Eye and Ear
  • Massachusetts General Hospital
  • MassBiologics
  • Matica Biotechnology
  • MaxCyte
  • Mayflower Bioscience
  • Mayo Clinic Cancer Center
  • McMaster Immunology Research Centre (MIRC)
  • MD Anderson Cancer Institute
  • medac
  • Medigene
  • MedImmune
  • MeiraGTx
  • Memorial Sloan Kettering Cancer Center
  • Merck
  • MicroBiopharm Japan
  • Microsoft
  • Mila’s Miracle Foundation
  • MilliporeSigma
  • Milo Biotechnology
  • Miltenyi Biotec
  • Minerva Biotechnologies
  • MingJu Therapeutics
  • Mitsubishi Tanabe Pharma
  • Moderna
  • Molecular Diagnostic Services
  • MolMed (acquired by AGC Biologics)
  • Momotaro-Gene
  • MultiVir
  • Mustang Bio
  • Mycenax Biotech
  • Myeloma Crowd
  • Nanjing Bioheng Biotech
  • Nantes Gene Therapy Institute
  • Naobios (a subsidiary of Clean Biologics)
  • National Cancer Institute
  • National Center for Advancing Translational Sciences
  • National Human Genome Research Institute
  • National Institute of Allergy and Infectious Diseases
  • National Institute of Environmental Health Sciences
  • National Institute of Neurodegenerative Disorders and Stroke
  • Nationwide Children's Hospital
  • Naval Medical Research Center
  • Neurimmune
  • NeuroCure
  • Neurophth Therapeutics
  • Neuroscience Center Zurich
  • New Jersey Innovation Institute (NJII)
  • NewLink Genetics
  • NHS Blood and Transplant
  • Nikon CeLL innovation
  • Noga therapeutics
  • Norgen Biotek
  • Northern RNA
  • NorthX Biologics
  • Nouscom
  • Novartis
  • Novartis Gene Therapies
  • Novasep
  • Novavax
  • OBiO Technology
  • Odylia Therapeutics
  • OHSU Casey Eye Institute
  • Okairos
  • Omnia Biologics
  • OmniaBio
  • Oncolys BioPharma
  • OncoSenX
  • ORCA Therapeutics
  • Oregon Health & Science University
  • Orgenesis
  • Otonomy
  • Oxford BioMedica
  • Oxford Genetics
  • OXGENE
  • OZ Biosciences
  • PackGene Biotech
  • PACT Pharma
  • Pall Biotech
  • Paragon Bioservices
  • Paras Biopharmaceuticals
  • Passage Bio
  • PeriphaGen
  • PerkinElmer
  • PersonGen BioTherapeutics
  • Peter MacCallum Cancer Centre
  • Pfizer
  • PharmaCell
  • pHion Therapeutics
  • PhorMed
  • Pinze Lifetechnology
  • PlasmidFactory
  • Porton Advanced Solutions
  • Poseida Therapeutics
  • Precigen
  • Precision BioSciences
  • Pregene Biotechnology
  • Prevail Therapeutics
  • Prime Vector Technologies
  • ProBioGen
  • PROGEN
  • Progenics Pharmaceuticals
  • ProMab Biotechnologies
  • Protheragen
  • Provecs Medical
  • PsiOxus Therapeutics
  • PTC Therapeutics
  • Puresyn
  • Quethera (acquired by Astellas Pharma)
  • Regeneron Pharmaceuticals
  • REGENXBIO
  • ReiThera
  • Renova Therapeutics
  • Rentschler Biopharma
  • Resilience
  • Richter-Helm BioLogics
  • Roche
  • Rocket Pharmaceuticals
  • Roswell Park Comprehensive Cancer Center
  • Rznomics
  • SAB Technology
  • SAFC
  • Saiba Biotech
  • Salk
  • Sanford Burnham Prebys
  • Sangamo Therapeutics
  • Sanofi
  • Santen Pharmaceutical
  • Sarepta Therapeutics
  • Sartorius Stedim Biotech
  • Scancell
  • Scorpius BioManufacturing
  • Seattle Children's Research Institute (SCRI)
  • Selecta Biosciences
  • Sensorion
  • Senti Biosciences
  • Servier
  • Shanghai Biomed-Union Biotechnology
  • Shanghai Bioray Laboratory
  • Shanghai Cell Therapy Group
  • Shanghai GeneChem
  • Shanghai Longyao Biotechnology
  • Shanghai PerHum Therapeutics
  • Shanghai Sunway Biotech
  • Shanghai Unicar-Therapy Bio-medicine Technology
  • Shenzhen Binde Biotechnology
  • Shenzhen Sibiono GeneTech
  • SignaGen Laboratories
  • SillaJen
  • Simcere Pharmaceutical
  • Sinobioway Cell Therapy
  • SIRION Biotech
  • Skyline Therapeutics
  • Solid Biosciences
  • Sorrento Therapeutics
  • Southern RNA
  • Spark Therapeutics
  • SQZ Biotechnologies
  • St. Jude Children's Research Hospital
  • Stanford University
  • Symbiosis Pharmaceutical Services
  • Synpromics
  • Synthace
  • System Biosciences
  • Takara Bio
  • Takeda Pharmaceutical
  • Tamid Bio (a subsidiary of Fortress Biotech)
  • Targovax
  • Taysha Gene Therapies
  • TCR2 Therapeutics
  • TCRCure Biopharma
  • tebu-bio
  • Telethon Institute of Genetics and Medicine (TIGEM)
  • Terry Fox Laboratory
  • Tessa Therapeutics
  • The Beijing Pregene Science and Technology
  • The Hong Kong Institute of Biotechnology
  • The Hormel Institute
  • The Jackson Laboratory
  • The Jenner Institute
  • The Michael J. Fox Foundation
  • The Native Antigen Company
  • The University of Queensland
  • The University of Tennessee Health Science Center
  • The Vector Core, University of North Carolina
  • Themis (acquired by Merck)
  • TheraBiologics
  • TheraVectys
  • Thermo Fisher Scientific
  • Tianjin Mycure Medical Technology
  • Timmune Biotech
  • Tmunity Therapeutics
  • Tolerion
  • Touchlight
  • Transgene
  • Treadwell Therapeutics
  • Treeway
  • TriLink BioTechnologies (a subsidiary of Maravai LifeSciences)
  • Trizell
  • Twist Bioscience
  • TxCell
  • uBriGene Biosciences
  • UC Davis
  • UC San Diego School of Medicine
  • UK Cystic Fibrosis Gene Therapy Consortium
  • Ultragenyx Pharmaceutical
  • uniQure
  • Univercells
  • University Hospital Tuebingen
  • University Medical Center Groningen
  • University of Adelaide
  • University of California
  • University of Eastern Finland
  • University of Florida
  • University of Iowa
  • University of Maryland
  • University of Michigan Health
  • University of Minnesota
  • University of North Carolina
  • University of Pennsylvania
  • University of Pittsburgh
  • University of South Carolina School of Medicine
  • University of Southampton
  • University of Tennessee Health Science Center
  • University of Tokyo
  • University of Virginia School of Medicine
  • Urovant Sciences
  • USC School of Pharmacy
  • UT Southwestern Medical Center
  • Vaccine Manufacturing and Innovation Centre (VMIC)
  • Vaccitech
  • VBL Therapeutics
  • VCN Biosciences
  • Vectalys
  • Vector Biolabs
  • Vector BioMed
  • VectorBuilder
  • Vecura
  • Versiti Blood Research Institute
  • VGXI
  • Vibalogics (acquired by Recipharm)
  • Vigene Biosciences (acquired by Charles River Laboratories)
  • Vineti
  • Viralgen (a subsidiary of Asklepios BioPharmaceutical)
  • Virapur
  • ViraQuest
  • ViroCell Biologics
  • ViroMed
  • Virovek
  • VIVEbiotech
  • Voyager Therapeutics
  • VVector Bio
  • VWR (a subsidiary of Avantor)
  • Wacker Biotech
  • Waisman Biomanufacturing
  • Washington University School of Medicine
  • Wellington Zhaotai Therapies
  • WhiteLab Genomics
  • Wuhan Bio-Raid Biotechnology
  • Wuhan Sian Medical Technology
  • WuXi AppTec
  • Wyvern Pharmaceuticals
  • Xiangxue Life Sciences
  • Xpress Biologics
  • XyloCor Therapeutics
  • Xyphos Biosciences
  • Yake Biotechnology
  • Yonsei University Health System
  • Yposkesi
  • Yufan Biotechnologies
  • Ziopharm Oncology

Methodology

 

 

Loading
LOADING...

Related Topics

Related Reports

Automated and Closed Cell Therapy Processing Systems Market Report 2026 - Product Image

Automated and Closed Cell Therapy Processing Systems Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Automated & Closed Cell Therapy Processing Systems Market - Global Forecast 2026-2032 - Product Image

Automated & Closed Cell Therapy Processing Systems Market - Global Forecast 2026-2032

  • Report
  • 182 Pages
  • Global
From
Automated and Closed Cell Therapy Processing Systems Market Size, Share & Trends Analysis Report by Workflow (Separation, Expansion, Apheresis), Type (Stem Cell Therapy), Scale (Commercial Scale), and Region with Growth Forecasts, 2026-2033 - Product Image

Automated and Closed Cell Therapy Processing Systems Market Size, Share & Trends Analysis Report by Workflow (Separation, Expansion, Apheresis), Type (Stem Cell Therapy), Scale (Commercial Scale), and Region with Growth Forecasts, 2026-2033

  • Report
  • 130 Pages
  • Global
From
Automated and Closed Cell Therapy Processing Systems Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031 - Product Image

Automated and Closed Cell Therapy Processing Systems Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

  • Report
  • 185 Pages
  • Global
From
Cell Therapy Manufacturing Market (7th Edition): Trends and Forecast Till 2035 - Distribution by Type of Cell Therapy, Source of Cells, Scale of Operation, Type of Manufacturer, and Geography - Product Image

Cell Therapy Manufacturing Market (7th Edition): Trends and Forecast Till 2035 - Distribution by Type of Cell Therapy, Source of Cells, Scale of Operation, Type of Manufacturer, and Geography

  • Report
  • 656 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.